Silvana Guerriero

Prof. Silvana Guerriero


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2011 in Brain
Verified
Journal Article
Open access
PDF file
Valerio CarelliValerio Carelli
Valerio Carelli
Chiara La MorgiaChiara La Morgia
Chiara La Morgia
MVMaria Lucia Valentino
Maria Lucia Valentino
GRGiovanni Rizzo
Giovanni Rizzo
MCMichele Carbonelli
Michele Carbonelli
PBPiero Barboni
Piero Barboni
Overall, 103 patients with LHON, carrying a primary mitochondrial DNA mutation were included in this study. Forty-four patients (37 males) were either treated w

16 December 2016 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
Claudia FabianiClaudia Fabiani
Claudia Fabiani
AVAntonio Vitale
Antonio Vitale
GEGiacomo Emmi
Giacomo Emmi
GLGiuseppe Lopalco
Giuseppe Lopalco
LVLorenzo Vannozzi
Lorenzo Vannozzi
LCLuca Cantarini
Luca Cantarini

16 November 2016 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
Claudia FabianiClaudia Fabiani
Claudia Fabiani
AVAntonio Vitale
Antonio Vitale
GEGiacomo Emmi
Giacomo Emmi
LVLorenzo Vannozzi
Lorenzo Vannozzi
GLGiuseppe Lopalco
Giuseppe Lopalco
LCLuca Cantarini
Luca Cantarini

15 April 2018 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
VCVanessa Cecchin
Vanessa Cecchin
MZMaria Elisabetta Zannin
Maria Elisabetta Zannin
DFDaniele Ferrari
Daniele Ferrari
IPIrene Pontikaki
Irene Pontikaki
EMElisabetta Miserocchi
Elisabetta Miserocchi
FZFrancesco Zulian
Francesco Zulian
Objective.: Anti-TNF-α agents have significantly changed the management of juvenile idiopathic arthritis (JIA). We evaluated the safety and efficacy of adalimumab (ADA) and infliximab (IFX) for the treatment of JIA-associated uveitis in patients treated for ≥ 2 years.Methods.: Patients with JIA-associated uveitis treated with IFX and ADA were managed by a standardized protocol and data were entered in the ORCHIDEA registry. At baseline, all patients were refractory to standard immunosuppressive treatment or were corticosteroid-dependent. Data recorded every 3 months were uveitis course, number/type of ocular flares and complications, drug-related adverse events (AE), and treatment switch or withdrawal. Data of patients treated for ≥ 2 years were analyzed by descriptive statistics.Results.: Up to December 2014, 154 patients with ≥ 24 months followup were included in the study. Fifty-nine patients were treated with IFX and 95 with ADA. Clinical remission, defined as the absence of flares for > 6 months on treatment, was achieved in 69 patients (44.8%), with a better remission rate for ADA (60.0%) as compared to IFX (20.3%; p < 0.001). A significant reduction of flares was observed in all patients without difference between the 2 treatment modalities. The number of new ocular complications decreased in both groups but was lower for ADA (p = 0.015). No serious AE were recorded; 16.4% of patients experienced 35 minor AE and the incidence rate was lower with ADA than with IFX.Conclusion.: At the 2-year followup, ADA showed a better efficacy and safety profile than IFX for the treatment of refractory JIA-associated uveitis.

11 August 2018 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
Claudia FabianiClaudia Fabiani
Claudia Fabiani
AVAntonio Vitale
Antonio Vitale
Donato RiganteDonato Rigante
Donato Rigante
GEGiacomo Emmi
Giacomo Emmi
ABAlice Bitossi
Alice Bitossi
LCLuca Cantarini
Luca Cantarini

18 December 2008 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Closed access
PDF file
DCD. Cave
D. Cave
RMRosa Monno
Rosa Monno
PBP. Bottalico
P. Bottalico
SGSilvana Guerriero
Silvana Guerriero
SDS. D’aMelio
S. D’aMelio
FBFederica Berrilli
Federica Berrilli